指南回顾播客 | 评估食物对研究性新药申请(IND)和新药申请(NDA)中药物的影响——临床药理学考量
正文 · 中文译文
指南回顾播客|评估食品对IND和NDA中药物的影响——临床药理学考量 指南|药物 CDER指南议程 仿制药开发的产品特定指南 指南快照试点 播客 感谢您收听本期指南回顾播客。我叫Kylie Haskins,是今天的主持人。在本期节目中,我很高兴能与传染病药理学分部治疗审评副主任Vikram Arya博士以及肿瘤药理学一部主任Brian Booth博士交谈。两位都在CDER的临床药理学办公室工作。Arya博士和Booth博士将与我们分享他们对新发布的最终指南《评估食品对IND和NDA中药物的影响——临床药理学考量》的一些看法。欢迎Arya博士和Booth博士。感谢你们今天与我们交谈。 让我们从Arya博士开始。您能向听众解释为什么评估食品对药物的影响很重要,并提供FDA发布本文件的一些原因吗? 是的,我很乐意。口服药物通过我们消化系统的胃肠道进入体内。评估食物对药物的影响很重要,因为食物可以影响胃肠道的生理功能,从而改变我们身体吸收某些药物的能力。某些类型的食物可以使特定药物的吸收增加或减少,而其他类型的食物可能对同一药物的吸收不显示任何影响。评估食物对药物的影响很重要,因为食物可以对药物的安全性和有效性产生显著影响。如果食物增加了药物的吸收,可能导致不良事件和副作用数量的增加。相反,如果食物降低了药物的吸收,则有可能使药物疗效降低。 FDA发布本文件旨在为开展食物影响研究提供最佳实践。从药物开发和监管审评的角度来看,我们关注三个方面的考量。首先,我们希望评估药物的吸收是否受到进食的影响。其次,如果食物确实对药物的吸收有影响,我们接下来想了解哪种类型的食物影响药物的吸收,并确定每种食物类型的具体影响。最后,我们希望全面审查研究结果,并在处方信息中制定实用的进食说明,解释何时服药相对于进食影响药物吸收的食物的关系。 接下来两个问题给Booth博士。药物开发过程中应在何时开展食物影响研究? 美国食品药品监督管理局(FDA)建议在开发早期开展食物影响研究。一般来说,应在首次人体单次给药试验中开展初步食物评估(称为试点食物影响评估)。在这一初步评估中,一组受试者会在进食和未进食状态下接受药物给药。这项初始研究并非确定性的食物影响研究,而是初步评估,有助于为药物开发的后续阶段确定给药策略,直至确定拟上市制剂。当确定拟上市制剂后,我们建议在开展关键安全性和有效性试验之前,开展一项关键食物影响试验,以评估食物对拟上市制剂的影响,从而确保在处方信息中能够描述与 food intake 相关的给药说明。 食物影响研究应纳入哪些类型的食物? 我们建议,对于所有在研的口服给药药物,应使用高脂餐进行食物效应研究,因为高脂餐通常对药物吸收的影响最大。如果药物在高脂餐条件下吸收显著增加或减少,那么评估其他餐食类型对药物药代动力学的影响可能很重要,因为其他类型的餐食影响可能较小,而这些信息可以提供关于伴随食物摄入的实用给药说明,有可能提高患者依从性。 Arya博士,接下来的两个问题是为您准备的。设计食物效应研究时有哪些一般性考虑? 通常,一项独立食物效应试验采用随机、单剂量、交叉设计,并设有充分的洗脱期。受试者接受单剂量药物,同时评估餐食条件,如高脂餐,或许还有低脂餐,或在至少10小时过夜禁食后给药。在研究期间,于预先指定的时间点从受试者采集血浆样本以评估药代动力学参数,然后对这些参数进行比较,以评估食物对药物药代动力学的影响。 最终,我们试图制定一套实用的给药说明,以便能够方便地给予药物的安全有效剂量。例如,在某些情况下,由于药物一天内需多次给药,两次给药之间禁食8-10小时可能并不实际,甚至不可能。然而,如果食物显著增加或降低药物的暴露量,则可能有必要采用禁食条件。在这些情况下,我们必须确定一个对患者切实可行的禁食时间框架,同时还要确定该禁食时间框架将确保药物的给药安全有效。 为了能够制定合适的给药说明,该指南建议在考虑给药频率、患者人口学特征、疾病状况以及任何其他相关因素后,开展一项具有适当且切实可行的间隔时间的食物效应研究,以确定食物摄入与药物给药之间应错开多长时间以避免食物效应。 您能否向我们简要概述一下该指南的演变过程? 本指南定稿了2019年2月发布的草案版本,并修订和替代了2002年FDA题为《食物效应生物利用度和餐后生物等效性研究》的指南。关于在简化新药申请(ANDAs)中提交的餐后生物等效性研究的信息,现可参见FDA行业指南《根据ANDA提交的药物采用药代动力学终点的生物等效性研究》。关于餐后可比性试验的具体建议,现已在FDA行业指南《在NDA或IND中提交的生物利用度研究——一般考虑》中描述。修订本指南相较于2002年发布的上一版本的一个关键目标是将指南重点放在食物效应试验设计和实施的临床药理学考虑方面。与这一目标一致,我们做出了若干关键修订,希望听众会觉得有帮助。即,我们专门设立了一个关于初步食物效应评估的章节,定义了低脂餐的组成以促进实用给药说明的制定,增加了在临床推荐剂量(而非最高规格)下评估食物效应的建议,认可了基于模型引导的药物开发方法在食物效应评估中不断演变的作用,并扩展了标签建议章节以反映当前的标签实践。 最后一个问题给Booth博士。您特别希望听众记住的几个关键要点是什么? 这是个很好的问题。我希望听众记住,食物可以升高或降低各种药物的血药浓度,这可能导致不良反应发生率或疗效升高或降低。在某些情况下,食物可用于改善引起胃肠道不适的药物的耐受性。设计良好的食物效应(FE)研究可以为药物是否应与食物同服、何时同服以及为何同服提供依据。药物研发者应在药物开发早期评估食物对新药药代动力学的影响,以指导整体药物开发计划并为最终产品说明书提供信息。本最终指南的发布旨在为口服药物产品的食物效应研究实施提供建议。 Arya博士和Booth博士,感谢你们今天与我们讨论关于评估食物对研究性新药申请(IND)和新药申请(NDA)中药物影响的临床药理学考虑的最终指南。我们从你们对该文件内容丰富的讨论中学到了很多。我们还要感谢指南工作组撰写并发布了本最终指南。 各位听众,我们希望你们觉得本期播客有用。我们鼓励你们查看快照并阅读该指南。 讲者简介 Vikram Arya博士 Vikram Arya 是前美国食品药品监督管理局(FDA)药品评价与研究中心(CDER)临床药理学办公室(OCP)感染性疾病药理学部(DIDP)治疗审评副主任,以及食物效应指南修订工作组联合主席。他主要负责在监管科学、政策实施和药物监管领域为多学科科学专业团队提供技术和战略领导。在此之前,他是OCP的主审评员和团队负责人,在监管申报的临床药理学方面审评以及抗病毒药物的获益/风险评估方面做出了广泛贡献。他是FDA杰出服务奖、FDA杠杆与协作奖、FDA团队表彰奖、CDER卓越领导奖以及多项CDER监管科学卓越奖和团队卓越奖的获得者,以表彰他对多种监管科学和政策制定倡议的贡献。他是政府卓越(EIG)研究员项目的研究员。他目前担任美国临床药理学学院(ACCP)前任主席,是ACCP研究员,以及《临床药理学杂志》(JCP)编委会成员。 Brian Booth,博士。 Brian Booth,博士,是美国食品药品监督管理局(FDA)临床药理学办公室癌症药理学一部的主任。Booth博士于1988年在麦吉尔大学获得生理学理学学士学位,随后在加拿大皇后大学攻读药理学与毒理学博士学位(1993年)。之后他在纽约州立大学布法罗分校药剂学系完成博士后研究,期间研究了一氧化氮供体与神经肽降钙素基因相关肽之间的相互作用。Booth博士于1998年加入FDA临床药理学与生物药剂学办公室。2004年,在担任该部门的审评员/药理学计量学家之后,他成为肿瘤药品部的代理团队负责人。2006年11月,Booth博士被任命为临床药理学五部副主任。在FDA,Booth博士参与了数百种新型肿瘤药物的临床药理学开发,涵盖1期至4期。除IND和NDA/BLA审评外,Booth博士还参与了新临床药理学审评员和医学官员的教学与培养,分析方法验证、食物效应、ARA药物相互作用、ADC药物、脂质体药品、PD-1/PD-L1以及肝功能损害研究行业指南的制定,以及临床药理学建模与模拟项目。他撰写了81篇同行评审文章和书籍章节。 内容截至日期: 2026年7月7日 受监管产品 药品
正文 · 英文原文
Guidance Recap Podcast | Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations Guidances | Drugs CDER Guidance Agenda Product-Specific Guidances for Generic Drug Development Guidance Snapshot Pilot Podcast Thank you for joining us for another episode of the Guidance Recap Podcast. My name is Kylie Haskins, and I am today’s host. In this episode, I am excited to be talking with Dr. Vikram Arya, the Associate Director for Therapeutic Review in the Division of Infectious Disease Pharmacology and Dr. Brian Booth, the Director of the Division of Cancer Pharmacology I. Both are in CDER’s Office of Clinical Pharmacology. Dr. Arya and Dr. Booth will be sharing some thoughts with us on the newly published final guidance titled, “Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations.” Welcome, Dr. Arya and Dr. Booth. Thank you for speaking with us today. Let’s begin with Dr. Arya. Can you explain to the audience why assessing the effects of food on drugs is important and provide some of the reasons that FDA issued this document? Yes, I’d be happy to. Orally administered drugs enter the body through the gastrointestinal tract of our digestive system. Assessing the effect of food on drugs is important because food can affect the physiology of the gastrointestinal tract and thereby alter the ability of our body to absorb certain drugs. Some types of food can cause the absorption of a specific drug to increase or decrease, and other types of food may not show any effect on the absorption of the same drug. It is important to assess the effect of food on a drug because food can have a significant impact on the safety and effectiveness of the drug. If the absorption of the drug is increased by food, it can cause an increase in the number of adverse events and side effects. Conversely, if food decreases the absorption of the drug, it has the potential to make the drug less effective. The FDA issued this document to provide best practices for conducting food effects studies. From a drug development and regulatory review standpoint, we are interested in three broad considerations. First, we want to assess if the absorption of a drug is affected by the consumption of food. Second, if food does have an effect on a drug’s absorption, we next want to understand what type of food affects the drug’s absorption and also identify the specific effect of each food type. Lastly, we want to comprehensively review the study results and develop practical food intake instructions in the prescribing information that explain when to take the drug relative to eating food that affects the drug’s absorption. The next two questions are for Dr. Booth. When should food effects studies be conducted during drug development? The FDA recommends conducting food effect studies early in development. Generally speaking, a preliminary food assessment (called the pilot food effect assessment) should be conducted as part of the first-in-human single dose trial. In this preliminary assessment, a cohort of subjects are administered the drug in the presence and absence of food. This initial study is not a definitive food effect study, rather a preliminary assessment that helps inform dosing strategies for subsequent phases of drug development until a to-be-marketed formulation is identified. When a to-be-marketed formulation is identified, we recommend conducting a pivotal food effect trial to assess the effect of food on the to-be-marketed formulation before conducting the pivotal safety and efficacy trials to ensure that the dosing instructions in relation to food intake can be described in the prescribing information. What types of foods should be included in a food effects study? We recommend that for all orally administered drugs under development, a food effect study should be conducted with a high-fat meal because high-fat meals generally have the biggest effect on drug absorption. If a drug shows a significant increase or decrease in absorption with a high fat meal, then evaluating the effect of additional meal types on the pharmacokinetics of the drug could be important because other types of meals may have a lesser effect, and this information can provide practical dosing instructions regarding concomitant food intake that could potentially improve patient compliance. Dr. Arya, the next two questions are for you. What are some general considerations for designing food effects studies? Generally, a standalone food effect trial follows a randomized, single-dose, crossover design with an adequate washout period. Subjects receive a single dose of the drug with the meal conditions being evaluated such as a high fat meal and perhaps a low fat meal or after fasting overnight for at least 10 hours. Plasma samples are collected from the subjects during the study at predesignated time points to assess the pharmacokinetic parameters, and these parameters are then compared to assess the effect of food on the pharmacokinetics of the drug. Ultimately, we are trying to develop a practical set of dosing instructions so that the safe and effective dose of the drug can be conveniently administered . For example, there may be cases where fasting for 8-10 hours between doses may not be practical or even possible because the drug is given multiple times a day. However, if food significantly increases or decreases the exposure of the drug, fasting conditions may be necessary. In these cases, we have to determine a fasting timeframe that is practical for the patient while also determining that the fasting timeframe will ensure the administration of the drug will be safe and effective. To be able to develop suitable dosing instructions, the guidance recommends conducting a food effects study with appropriate and practical separation times after considering the frequency of dosing, patient demographics, disease condition, and any other relevant factors in order to determine how much time should be staggered between food consumption and the drug administration to avoid the food effect. Can you give us a brief overview of the evolution of this guidance? This guidance finalizes the draft version issued in February 2019, and revisesand replaces the 2002 FDA guidance titled Food-Effect Bioavailability and Fed Bioequivalence Studies. Information on fed bioequivalence studies to be submitted in abbreviated new drug applications (ANDAs) is now found in the FDA guidance for industry titled Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Specific recommendations concerning fed comparability trials are now described in the FDA guidance for industry titled Bioavailability Studies Submitted in NDAs or INDs — General Considerations. A key goal for revising this guidance from the previous version issued in 2002 was to focus the guidance on the clinical pharmacology considerations for the design and conduct of food effect trials. In line with this goal, we have made several key revisions that we hope listeners will find helpful. Namely, we dedicated a section on pilot food effect assessments, defined the composition of a low fat meal to facilitate development of practical dosing instructions, added a recommendation to assess the food effects at the clinically recommended dose (and not the highest strength), acknowledged the evolving role of Model Informed Drug Development based approaches for food effect assessment and expanded the labeling recommendations section to reflect current labeling practices. The last question is for Dr. Booth. What are a couple of key items that you especially want listeners to remember? That’s a great question. I’d like listeners to remember that food can increase or decrease blood levels of various drugs, which can lead to higher or lower rates of adverse reactions or efficacy. In some cases, food can be used to improve tolerability of a drug that causes GI discomfort. Well-conducted FE studies can inform how, when, and why drugs should or should not be administered with food. Drug developers should assess the effect of food on the pharmacokinetics of a new drug early in its development to guide the overall drug development program and inform final product labeling. This final guidance has been issued to provide recommendations on the conduct of food effect studies for orally administered drug products. Dr. Arya and Dr. Booth, thank you for speaking with us today about the final guidance on the clinical pharmacology considerations for assessing the effects of food on drugs in INDs and NDAs. We have learned so much from your informative discussion on the document. We would also like to thank the guidance working group for writing and publishing this final guidance. To the listeners, we hope you found this podcast useful. We encourage you to take a look at the snapshot and to read the guidance. Speaker Biographies Vikram Arya, Ph.D. Vikram Arya is the former Associate Director for Therapeutic Review in the Division of Infectious Disease Pharmacology (DIDP) in the Office of Clinical Pharmacology (OCP), CDER, FDA and Co-Chair of the Food Effect Guidance Revision Working Group. He was primarily responsible for providing technical and strategic leadership in the areas of regulatory science, policy implementation, and drug regulation to a multi-disciplinary group of scientific professionals. Prior to this role, he was a master reviewer and team leader in OCP and extensively contributed to the review of clinical pharmacology aspects of regulatory submissions and benefit/risk assessment of antiviral drugs. He is the recipient of the FDA Outstanding Service Award, FDA Leveraging and Collaboration Award, FDA Group Recognition Award, CDER Leadership Excellence Award and several CDER Regulatory Science Excellence and Team Excellence Awards to recognize his contributions to a variety of regulatory science and policy setting initiatives. He is a fellow of the Excellence in Government (EIG) Fellows Program. He currently serves as the Immediate Past President of the American College of Clinical Pharmacology (ACCP), is a fellow of ACCP, and an Editorial Board member of the Journal of Clinical Pharmacology (JCP). Brian Booth, Ph.D. Brian Booth, Ph.D. is the Director of the Division of Cancer Pharmacology I, in the Office of Clinical Pharmacology at the U.S. Food and Drug Administration. Dr. Booth obtained a Bachelor of Science in Physiology at McGill University in 1988, and subsequently pursued a Doctorate in Pharmacology and Toxicology at Queen’s University (1993) in Canada. Following a Post-Doctoral Fellowship in the Department of Pharmaceutics at the State University of New York at Buffalo, where he studied the interaction between nitric oxide donors and the neuropeptide calcitonin gene-related peptide. Dr. Booth joined the Office of Clinical Pharmacology and Biopharmaceutics, FDA, in 1998. In 2004, he became the Acting Team Leader in the Division of Oncology Drug Products, after serving as a reviewer/pharmacometrician in this division. In November 2006, Dr. Booth was appointed as Deputy Director of the Division of Clinical Pharmacology V. At the FDA, Dr. Booth has been involved with the clinical pharmacology development of several hundred new oncology drugs, ranging from phase 1 to phase 4. In addition to IND and NDA/BLA reviews, Dr. Booth has been involved with teaching and development of new clinical pharmacology reviewers and medical officers, development of the analytical method validation, food effects, ARA drug-drug interactions, ADC- drugs, liposome drug product, PD-1/PD-L1 and studies in hepatic impairment Guidances for Industry, and clinical pharmacology modeling and simulation projects. He has authored 81 peer reviewed articles and book chapters. Content current as of: 07/07/2026 Regulated Product(s) Drugs